These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38623708)

  • 1. Understanding the treatment paradigm and the sequencing of antiglaucoma fixed-dose combinations in a tertiary center in South India.
    George R; Mishra P; Shantha B; Vijaya L; Maksane N; Gurha N
    Indian J Ophthalmol; 2024 Jun; 72(6):896-901. PubMed ID: 38623708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series.
    Joh HJ; Jin SW
    Jpn J Ophthalmol; 2019 Jul; 63(4):322-327. PubMed ID: 31115761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.
    Rhee T; Kim J; Ha A
    Korean J Ophthalmol; 2024 Jun; 38(3):221-226. PubMed ID: 38665112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Mishra A; Agrawal M; Tripathi A; Bhirud A; Kumar LCR; Vinod K BB
    J Ocul Pharmacol Ther; 2024 May; 40(4):240-245. PubMed ID: 38598266
    [No Abstract]   [Full Text] [Related]  

  • 5. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular pressure changes following topical ocular hypotensive medications washout.
    Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
    Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma.
    Wy S; Kim YK; Jeoung JW; Park KH; Ha A
    Korean J Ophthalmol; 2020 Feb; 34(1):19-26. PubMed ID: 32037746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
    Kóthy P; Holló G
    Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.
    Zhao JL; Ge J; Li XX; Li YM; Sheng YH; Sun NX; Sun XH; Yao K; Zhong Z;
    BMC Ophthalmol; 2011 Aug; 11():23. PubMed ID: 21851642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
    Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
    J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.